Literature DB >> 27193208

Is mucin a determinant of peritoneal dissemination of gastrointestinal cancer? Analysis of mucin depletion in two preclinical models.

S Masoumi-Moghaddam1, A Amini2, D L Morris2.   

Abstract

BACKGROUND: Mucinous gastrointestinal cancers may indicate a higher propensity for widespread peritoneal seeding than their non-mucinous counterparts. We hypothesized that mucin content of gastrointestinal cancer cells and tumors is an indicator of cell viability and a determinant of the peritoneal tumor burden and tested our hypothesis in relevant experimental models.
METHODS: MKN45 and LS174T models of human gastrointestinal cancer were treated with known mucin-depleting agents in vitro and in vivo, their mucin production was evaluated with Western blot immunohistochemistry, PAS staining and ELISA, and its correlation with cell viability and peritoneal tumor burden was analyzed.
RESULTS: A relationship was found between the viability of cancer cells and their mucin levels in vitro. In agreement, when treated animal models were categorized into low- and high-burden groups (based on the weight and number of the peritoneal nodules), tumoral mucin levels were found to be significantly higher in the latter group.
CONCLUSIONS: Tumoral mucin is apparently among the factors that dictate the pattern and extent of the peritoneal spread of gastrointestinal cancer, where it allows for enhanced dissemination and redistribution. If further tested and validated, our hypothesis could lay the basis for the development of novel mucin-targeted strategies.

Entities:  

Keywords:  Gastrointestinal cancer; MUC1; MUC2; MUC5AC; Mucin; Peritoneal dissemination

Mesh:

Substances:

Year:  2016        PMID: 27193208     DOI: 10.1007/s12094-016-1519-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  15 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

Review 2.  Mucins in cancer: protection and control of the cell surface.

Authors:  Michael A Hollingsworth; Benjamin J Swanson
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

3.  Peritoneum as the first-line of defense in carcinomatosis.

Authors:  Paul H Sugarbaker
Journal:  J Surg Oncol       Date:  2007-02-01       Impact factor: 3.454

4.  Utility of Bromelain and N-Acetylcysteine in Treatment of Peritoneal Dissemination of Gastrointestinal Mucin-Producing Malignancies.

Authors: 
Journal:  Anticancer Res       Date:  2016-06       Impact factor: 2.480

Review 5.  Mucins and tumor resistance to chemotherapeutic drugs.

Authors:  Nicolas Jonckheere; Nicolas Skrypek; Isabelle Van Seuningen
Journal:  Biochim Biophys Acta       Date:  2014-04-29

Review 6.  Mucins and mucin binding proteins in colorectal cancer.

Authors:  James C Byrd; Robert S Bresalier
Journal:  Cancer Metastasis Rev       Date:  2004 Jan-Jun       Impact factor: 9.264

7.  Intraperitoneal cancer dissemination: mechanisms of the patterns of spread.

Authors:  C Pablo Carmignani; Tessa A Sugarbaker; Christina M Bromley; Paul H Sugarbaker
Journal:  Cancer Metastasis Rev       Date:  2003-12       Impact factor: 9.264

Review 8.  Pseudomyxoma peritonei.

Authors:  P H Sugarbaker
Journal:  Cancer Treat Res       Date:  1996

Review 9.  MUC1: a multifaceted oncoprotein with a key role in cancer progression.

Authors:  Sritama Nath; Pinku Mukherjee
Journal:  Trends Mol Med       Date:  2014-03-22       Impact factor: 11.951

10.  Depletion of mucin in mucin-producing human gastrointestinal carcinoma: Results from in vitro and in vivo studies with bromelain and N-acetylcysteine.

Authors:  Afshin Amini; Samar Masoumi-Moghaddam; Anahid Ehteda; Winston Liauw; David L Morris
Journal:  Oncotarget       Date:  2015-10-20
View more
  1 in total

1.  Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.

Authors:  Murali R Kuracha; Peter Thomas; Brian W Loggie; Venkatesh Govindarajan
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.